隨著生活節(jié)奏的加快，偏頭痛的發(fā)病率呈逐漸增加的趨勢(shì)。目前用于治療偏頭痛的藥物主要為曲坦類(lèi)藥物，但由于該類(lèi)藥物會(huì)使血管收縮，因此對(duì)于心腦血管和周?chē)芗膊』颊呓谩Ｇ诡?lèi)藥物對(duì)中重度頭痛患者的療效顯著降低。因此，迫切需要開(kāi)發(fā)新的急性期治療藥物。lasmiditan是一種非曲坦類(lèi)的5-HT_1F受體激動(dòng)劑，多項(xiàng)臨床試驗(yàn)研究表明其具有良好的有效性和安全性。主要從lasmiditan的藥物概況、相關(guān)背景、合成路線(xiàn)、藥理作用、臨床研究和安全性等方面進(jìn)行介紹。

With the accelerated pace of life, the incidence of migraine was gradually increasing. Currently, drugs mainly used in treatment of migraine are triptans. While triptans can constrict blood vessels, they are prohibited for patients with cardiovascular and peripheral vascular diseases. And triptans have lower efficacy for moderate and severe patients. Therefore, it is necessary to find a novel therapeutic drug. lasmiditan is a selective 5-HT_1F receptor agonist, and many clinical studies show that lasmiditan has a good effectiveness and safety. The drug situation, background, route of synthesis, pharmacological action, clinical trials researches, and safety of lasmiditan are reviewed in this paper.